Evaluation of Food Supplementation in Subjects With Suboptimal Levels of LDL Cholesterol

This randomized, double-blind, placebo-controlled, parallel-group clinical study aims to evaluate the effect of a dietary supplement on LDL-cholesterol levels in healthy adults with suboptimal LDL-C values. Eligible participants will follow standard dietary recommendations based on the Mediterranean diet, according to the European Atherosclerosis Society guidelines. Subjects will be randomized to receive either the dietary supplement (1 tablet/day) or placebo (1 tablet/day), both in combination with dietary recommendations, over a treatment period of 12 weeks. The primary objective is to compare the effect of the tested food supplement versus placebo on LDL-cholesterol after 12 weeks of treatment. Secondary objectives include evaluating changes in LDL-cholesterol at 6 weeks, other lipid fractions, homocysteine, glucose and insulin levels, hsCRP, anthropometric parameters, as well as tolerability and acceptability of the supplement. Safety will be assessed through the collection of adverse events. Study participation lasts approximately 16 weeks, including screening, diet stabilization run-in, treatment, and follow-up assessments. Outcome measures will be collected at baseline, after 6 weeks, and after 12 weeks of treatment.

Inclusion Criteria: The subjects will have to meet all the following inclusion criteria: 1. Subjects agree to participate in the study and having dated and signed the informed consent form. 2. Subjects who have the capability to communicate, to make themselves understood, and to comply with the study's requirements. 3. Male or female aged ≥ 18 years and ≤ 70 years old. 4. LDL-Cholesterol plasma levels \>115 mg/dL and \< 190 mg/dL. 5. TG\ 5%; 2. Obesity (BMI\>30 kg/m2) or diabetes mellitus; 3. Assumption of lipid lowering drugs or food supplements, or drugs potentially affecting the lipid metabolism; 4. Antihypertensive treatment not stabilized since at least 3 months; 5. Anticoagulants therapy 6. Uncontrolled hypertension (systolic blood pressure\> 190 mmHg or diastolic arterial pressure\> 100 mmHg); 7. Known current thyroid, gastrointestinal or hepatobiliary diseases; 8. Any medical or surgical condition that would limit the patient adhesion to the study protocol; 9. Abuse of alcohol or drugs (current or previous); 10. History of malignant neoplasia in the 5 years prior to enrolment in the study; 11. History or clinical evidence of inflammatory disease such as severe arthritis, systemic lupus erythematosus or chronic inflammatory diseases or current therapy with immunosuppressive agents or long-term glucocorticoids; 12. History or clinical evidence of any significant concomitant disease that could compromise the safety of the subject or the possibility of completing the study; 13. Known previous intolerance to one component of the tested nutraceuticals 14. Women in fertile age not using consolidated contraceptive methods 15. Pregnancy and Breastfeeding.